Gilead’s Pipeline Strategy in 2026: A Broadening Focus Beyond HIV

Why It Matters

Diversifying beyond HIV is critical for Gilead to sustain growth and reduce revenue concentration risk, while the new oncology and immunology assets could become the next profit engines.

Key Takeaways

• Gilead spent $12.6 billion on three 2026 acquisitions
• Oncology central; Arcellx and Tubulis add CAR‑T and ADC platforms
• Gilead's HIV drug Yeztugo aims for $800 million 2026 sales
• New T‑cell engager OM336 targets autoimmune diseases, entering registrational studies 2027
• Trodelvy remains blockbuster despite trial setbacks, supporting oncology foothold

Pulse Analysis

Gilead’s 2026 strategy reflects a classic biopharma pivot: turning a revenue engine built on a single therapeutic class into a multi‑segment powerhouse. With HIV accounting for roughly 95% of its $20.8 billion sales, the company faces a looming patent cliff on Biktarvy and mounting competitive pressure from long‑acting injectables. By allocating over $12 billion to three strategic acquisitions, Gilead is not merely buying products but entire platforms—Arcellx’s D‑Domain CAR‑T technology, Tubulis’s next‑generation ADC pipeline, and Ouro’s T‑cell engager expertise—positioning itself to capture emerging markets in oncology and autoimmunity.

On the oncology front, Gilead now leans heavily on the promise of CAR‑T and ADC modalities to offset its reliance on Trodelvy, a blockbuster that has stumbled in several indications but still provides a foothold in cancer. The Arcellx deal accelerates the rollout of anito‑cel for multiple myeloma, while Tubulis adds TUB‑040 for platinum‑resistant ovarian and NSCLC. These assets broaden Gilead’s addressable market beyond hematologic cancers, offering a pipeline that could sustain growth for a decade if regulatory milestones are met.

In HIV, Gilead is betting on long‑acting therapies to retain market share. Yeztugo, the first twice‑yearly capsid inhibitor, is projected to deliver $800 million in 2026, but it must contend with GSK’s bimonthly Apretude, which enjoys higher patient preference. Simultaneously, the Ouro acquisition signals a tentative foray into autoimmune disease, leveraging T‑cell engagers to achieve deep, drug‑free remissions. If Gilead can translate these scientific advances into commercial successes, it will not only mitigate the HIV revenue cliff but also establish a diversified growth trajectory for the next decade.